Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival (Q34633368)

3 August 2017

Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival (English)

1 reference

3 August 2017

1 reference

11

A Le Cesne

0 references

Jean-Yves Blay

12

object named as

J-Y Blay

0 references

Samuel Singer

object named as

S Singer

16

0 references

author name string

A Italiano

1

1 reference

3 August 2017

M Toulmonde

2

1 reference

3 August 2017

A Cioffi

3

1 reference

3 August 2017

A Cioffi

4

1 reference

3 August 2017

N Penel

5

1 reference

3 August 2017

N Isambert

6

1 reference

3 August 2017

E Bompas

7

1 reference

3 August 2017

F Duffaud

8

1 reference

3 August 2017

A Patrikidou

9

1 reference

3 August 2017

B Lortal

10

1 reference

3 August 2017

R G Maki

13

1 reference

3 August 2017

G K Schwartz

14

1 reference

3 August 2017

C R Antonescu

15

1 reference

3 August 2017

J-M Coindre

17

1 reference

3 August 2017

B Bui

18

1 reference

3 August 2017

29 October 2011

1 reference

3 August 2017

1 reference

3 August 2017

23

1 reference

3 August 2017

6

1 reference

3 August 2017

1601-1607

1 reference

HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon.

3 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR485

MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR485

Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR485

Most malignant fibrous histiocytomas developed in the retroperitoneum are dedifferentiated liposarcomas: a review of 25 cases initially diagnosed as malignant fibrous histiocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR485

Added Value of Molecular Biological Analysis in Diagnosis and Clinical Management of Liposarcoma: A 30-Year Single-Institution Experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR485

The prognostic impact of dedifferentiation in retroperitoneal liposarcoma: a series of surgically treated patients at a single institution

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR485

Well-differentiated and dedifferentiated liposarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR485

Dedifferentiated liposarcoma: a clinicopathological analysis of 155 cases with a proposal for an expanded definition of dedifferentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR485

Differential sensitivity of liposarcoma subtypes to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR485

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR485

Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR485

Myxoid liposarcoma. Experience with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR485

Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR485

Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR485

Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR485

Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR485

Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR485

Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR485

Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR485

Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR485

Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR485

Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR485

Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR485

A phase II trial with rosiglitazone in liposarcoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR485

Involvement of c-jun in human liposarcoma growth: supporting data from clinical immunohistochemistry and DNAzyme efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR485

An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR485

Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR485

Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR485

Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR485

Performance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma: the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDR485

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDR485

1 reference

3 August 2017

1 reference